Table 5 Analytical specificity of MAGLUMI HIV Ab/Ag Combi in samples with potentially cross reacting substances/agents and interfering substances
From: Evaluation of the MAGLUMI HIV Ab/Ag combi test for the detection of HIV infection
Cross reacting and interfering substances/agents | Positive | Negative | |
|---|---|---|---|
Cross reacting substances/agents | Auto-immune diseases | 0 | 20 |
Pregnant women | 0 | 7 | |
Hyper IgG/IgM | 0 | 8 | |
Flu patients | 0 | 7 | |
Patients with chronic kidney disease/dialysis insufficiency (dialysis patients) | 0 | 7 | |
Anti-TP positive | 0 | 7 | |
Anti-HEV positive | 0 | 7 | |
Anti-HCV positive | 0 | 7 | |
Anti-EBV positive | 0 | 6 | |
Anti-CMV positive | 0 | 7 | |
Anti-VZV positive | 0 | 5 | |
Anti-HSV-1/2 positive | 0 | 6 | |
Anti-HAV positive | 0 | 6 | |
HBsAg positive | 0 | 6 | |
Anti-HBc positive | 0 | 4 | |
Interfering substances | Hemolytic Low (0.6 g/dL) | 0 | 3 |
Hemolytic Medium (1.0 g/dL) | 0 | 3 | |
Hemolytic High (1.9–2.0 g/dL) | 0 | 3 | |
Lipemic Low (213–270 mg/dL) | 0 | 3 | |
Lipemic Medium (440–556.3 mg/dL) | 0 | 3 | |
Lipemic High (872.9–1083 mg/dL) | 0 | 3 | |
Bilirubin (lcteric) Low (14.4–15.2 mg/dL) | 0 | 3 | |
Bilirubin (lcteric) Medium (20.8 mg/dL) | 0 | 3 | |
Bilirubin (lcteric) High (30.1–31.7 mg/dL) | 0 | 3 | |
Total | 0 | 137 | |
analytical specificity | 100.00% | ||
95% CI | 97.27%-100.00% |